Physician profile
Keith Swetz
NPI 1558348219
$1,293.91
in general payments reported to CMS, 2019-2025
20 companies · $1,277 in 2025
The $1,277 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.90 · 2025: $1,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $195.33 | 2025 | |
| Glaxosmithkline, LLC. | $188.36 | 2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $141.50 | 2025 | |
| Lilly USA, LLC | $133.09 | 2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $97.22 | 2025 | Airsupra, Breztri |
| Abbvie INC. | $80.64 | 2025 | |
| Merit Medical Systems INC | $69.58 | 2025 | Esophyx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.51 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $51.15 | 2022-2025 | Lagevrio |
| Abbott Laboratories | $46.01 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $32.20 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.19 | 2025 | Jardiance |
| Sumitomo Pharma America, INC. | $28.63 | 2025 | Gemtesa |
| Biogen, INC. | $27.24 | 2025 | Leqembi |
| Xeris Pharmaceuticals, INC. | $23.10 | 2025 | Recorlev |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.70 | 2025 | Krystexxa |
| Novo Nordisk INC | $18.52 | 2025 | Wegovy |
| Averitas Pharma INC. | $17.52 | 2025 | Qutenza |
| Lundbeck LLC | $16.16 | 2025 | Rexulti |
| Shield Therapeutics INC | $14.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Swetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.